



Marksans Pharma Ltd.

NEWS RELEASE

12th February 2016, Mumbai - India

Marksans Pharma Limited has reported today its financial performance for the Q3 FY 2015-16 and for the nine months period ended 31st December 2015.

Performance Highlights.

Marksans Consolidated Revenue up by 9.45% in nine months of FY 2015-16

Highlights of (Nine Months) FY 2015-16 Consolidated financial performance

- Total revenue grew 9.45% at Rs. 685.51 crores against Rs. 626.27 crores during the same period of FY 2014-15.
- EBITDA at Rs. 134.37 crores against Rs.146.22 crores.
- EBITDA at 19.60% of revenue.
- Profit before tax at Rs. 106.41 crores against Rs. 119.58 crores.
- Profit after tax at Rs. 84.27 crores against Rs. 84.35 crores. PAT at 12.29% of revenue.

Highlights of (Nine Months)FY 2015-16 Standalone financial performance

- Total revenue at Rs. 291.00 crores against Rs.313.86 crores during the same period of FY 2014-15
- EBITDA at Rs. 98.96 crores against 98.02 crores.
- Profit before tax was Rs. 83.22 crores against Rs. 79.79 crores.
- Post tax profit at Rs. 66.40 crores against Rs. 54.80 crores. PAT at 22.82% of revenue.

Revenue Figures - Consolidated

	INR in crores		
	First nine months of		Growth %
	FY 2015-16	FY 2014-15	
Europe, UK – Formulations	344.79	400.70	-13.95%
US & North America - Formulations	241.16	119.74	101.40%
Australia & NZ – Formulations	73.05	67.18	8.73%
Rest of World (ROW)	26.51	38.65	-31.41%
Consolidated Revenue from operations	685.51	626.27	9.45%

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com



Marksans Pharma Ltd.

Business Highlights

- Europe, UK Formulation business was at Rs. 344.79 crores during first nine months of FY 2015-16(As against Rs. 400.70 crores during last year same period). The degrowth was mainly on account of pricing pressure witnessed in UK markets.
- US & North America Formulation business grew at 101.40% to Rs.241.16 crores from Rs. 119.74 crores during first nine months of FY 2015-16.
- Company achieved revenue of Rs. 73.05 crores from Australia & NZ Formulation business.
- Rest of World Formulation business declined to Rs. 26.51 crores from Rs. 38.65 crores during first nine months of FY 2015-16.

About Marksans Pharma Limited

Marksans Pharma Limited(www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK MHRA, Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain management, Gastroenterologicals and Anti-allergies. The company is marketing these products globally.

Marksans Pharma Limited

11th Floor, Grandeur, Opp Gundecha Symphony, Veera Desai Extension Road,
Oshiwara, Andheri – West, Mumbai – 400 053, India

Tel:- +91 22 4001 2000, ax:- +91 22 4001 2011

CIN : L24110MH1992PLC066364

www.marksanspharma.com

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,
Andheri (W), Mumbai - 400 053 • Tel.: +91 22 4001 2000 • Fax : +91-22 4001 2011
E-mail: info@marksanspharma.com